Mononessa
Name: Mononessa
- Mononessa drug
- Mononessa brand name
- Mononessa dosage
- Mononessa dosage forms
- Mononessa side effects
- Mononessa serious side effects
- Mononessa effects of
- Mononessa the effects of
- Mononessa used to treat
- Mononessa is used to treat
- Mononessa effects of mononessa
- Mononessa mg
- Mononessa mononessa tablet
What Is Mononessa?
Ethinyl estradiol and norgestimate is a combination drug that contains female hormones that prevent ovulation (the release of an egg from an ovary). This medication also causes changes in your cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus.
Ethinyl estradiol and norgestimate is used as contraception to prevent pregnancy.
Ethinyl estradiol and norgestimate may also be used for purposes not listed in this medication guide.
Do not use birth control pills if you are pregnant or if you have recently had a baby.
You should not take birth control pills if you have any of the following conditions: unusual vaginal bleeding, chest pain, uncontrolled high blood pressure, an uncontrolled heart valve disorder, diabetic problems with your eyes or kidneys, liver cancer, severe migraine headaches, or if you have ever had breast or uterine cancer, jaundice caused by pregnancy or birth control pills, a heart attack, a stroke, or a blood clot.
Taking birth control pills can increase your risk of blood clots, stroke, or heart attack, especially if you have certain other conditions, or if you are overweight.
Smoking can greatly increase your risk of blood clots, stroke, or heart attack. You should not take birth control pills if you smoke and are over 35 years old.
Taking birth control pills can increase your risk of blood clots, stroke, or heart attack. You are even more at risk if you have high blood pressure, diabetes, high cholesterol, or if you are overweight. Your risk of stroke or blood clot is highest during your first year of taking birth control pills. Your risk is also high when you restart birth control pills after not taking them for 4 weeks or longer.
Smoking can greatly increase your risk of blood clots, stroke, or heart attack. Your risk increases the older you are and the more you smoke. You should not take combination birth control pills if you smoke and are over 35 years old.
Do not use if you are pregnant. Stop taking this medicine and tell your doctor if you become pregnant, or if you miss two menstrual periods in a row. If you have recently had a baby, wait at least 4 weeks before taking birth control pills.
You should not take birth control pills if you have:
- untreated or uncontrolled high blood pressure;
- heart disease (coronary artery disease, uncontrolled heart valve disorder, history of heart attack, stroke, or blood clot);
- chest pain;
- unusual vaginal bleeding that has not been checked by a doctor;
- problems with your eyes, kidneys or circulation caused by diabetes;
- a history of hormone-related cancer such as breast or uterine cancer;
- liver cancer;
- a history of jaundice caused by pregnancy or birth control pills; or
- severe migraine headaches (with aura, numbness, weakness, or vision changes).
To make sure birth control pills are safe for you, tell your doctor if you have:
- heart disease, high blood pressure;
- high cholesterol or triglycerides;
- a history of depression;
- gallbladder disease;
- liver or kidney disease;
- diabetes;
- seizures or epilepsy;
- a history of irregular menstrual cycles; or
- a history of fibrocystic breast disease, lumps, nodules, or an abnormal mammogram.
The hormones in birth control pills can pass into breast milk and may harm a nursing baby. This medication may also slow breast milk production. Do not use if you are breast feeding a baby.
What is the most important information I should know about birth control pills?
Do not use birth control pills if you are pregnant or if you have recently had a baby.
You should not take birth control pills if you have any of the following conditions: unusual vaginal bleeding, chest pain, uncontrolled high blood pressure, an uncontrolled heart valve disorder, diabetic problems with your eyes or kidneys, liver cancer, severe migraine headaches, or if you have ever had breast or uterine cancer, jaundice caused by pregnancy or birth control pills, a heart attack, a stroke, or a blood clot.
Taking birth control pills can increase your risk of blood clots, stroke, or heart attack, especially if you have certain other conditions, or if you are overweight.
Smoking can greatly increase your risk of blood clots, stroke, or heart attack. You should not take birth control pills if you smoke and are over 35 years old.
Commonly used brand name(s)
In the U.S.
- Estarylla
- MonoNessa
- Ortho-Cyclen
- Ortho Tri-Cyclen
- Ortho Tri-Cyclen Lo
- Previfem
- Sprintec
- Tri-Lo-Sprintec
- TriNessa
- TriNessa 28
- Tri-Previfem
- Tri-Sprintec
Available Dosage Forms:
- Tablet
Therapeutic Class: Triphasic Contraceptive Combination
Pharmacologic Class: Estrogen
Before Using MonoNessa
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies on the relationship of age to the effects of ethinyl estradiol and norgestimate combination have not been performed in the pediatric population. However, pediatric-specific problems that would limit the usefulness of this medication in teenagers are not expected. This medicine may be used for birth control in teenage females but should not be used before the start of menstruation.
Geriatric
Appropriate studies on the relationship of age to the effects of ethinyl estradiol and norgestimate combination have not been performed in the geriatric population. This medicine should not be used in elderly women.
Breast Feeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with Medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
- Dasabuvir
- Ombitasvir
- Paritaprevir
- Ritonavir
- Tranexamic Acid
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
- Anagrelide
- Aprepitant
- Boceprevir
- Bosentan
- Bupropion
- Carbamazepine
- Ceritinib
- Dabrafenib
- Darunavir
- Dexamethasone
- Donepezil
- Eliglustat
- Enzalutamide
- Fosphenytoin
- Griseofulvin
- Idelalisib
- Isotretinoin
- Lesinurad
- Lixisenatide
- Lumacaftor
- Mitotane
- Modafinil
- Oxcarbazepine
- Paclitaxel
- Paclitaxel Protein-Bound
- Phenytoin
- Piperaquine
- Pitolisant
- Prednisone
- Rifabutin
- Rifampin
- St John's Wort
- Sugammadex
- Theophylline
- Tizanidine
- Topiramate
- Ulipristal
- Valproic Acid
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
- Alprazolam
- Amprenavir
- Atazanavir
- Bacampicillin
- Betamethasone
- Bexarotene
- Clarithromycin
- Colesevelam
- Cyclosporine
- Delavirdine
- Efavirenz
- Eslicarbazepine Acetate
- Etoricoxib
- Fosamprenavir
- Fosaprepitant
- Ginseng
- Lamotrigine
- Licorice
- Mycophenolate Mofetil
- Mycophenolic Acid
- Nelfinavir
- Parecoxib
- Prednisolone
- Rifapentine
- Ritonavir
- Roflumilast
- Rosuvastatin
- Rufinamide
- Selegiline
- Telaprevir
- Tipranavir
- Troglitazone
- Troleandomycin
- Valdecoxib
- Voriconazole
- Warfarin
Interactions with Food/Tobacco/Alcohol
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following may cause an increased risk of certain side effects but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.
- Caffeine
- Grapefruit Juice
Other Medical Problems
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
- Abnormal or unusual vaginal bleeding or
- Blood clots (eg, deep vein thrombosis, pulmonary embolism), or history of or
- Breast cancer, known or suspected or
- Diabetes with kidney, eye, nerve, or blood vessel damage or
- Endometrial cancer or
- Heart attack, history of or
- Heart or blood vessel disease (eg, coronary artery disease, heart valve problems), or history of or
- Hypertension (high blood pressure) that is not under good control or
- Jaundice during pregnancy or from using hormonal therapy in the past or
- Liver disease, including tumors or cancer or
- Major surgery with prolonged periods of immobilization or
- Migraine headache or
- Stroke, history of or
- Tumors (estrogen-dependent), known or suspected—Should not be used in patients with these conditions.
- Breast cancer, family history of or
- Cervical cancer or
- Chloasma (skin discoloration of the face during pregnancy), history of or
- Depression, history of or
- Edema (fluid retention or body swelling) or
- Epilepsy (seizures) or
- Gallbladder disease or
- Hereditary angioedema or
- Hypertension (high blood pressure)—Use with caution. May make these conditions worse.
- Diabetes or
- Hyperlipidemia (high cholesterol or fats in the blood) or
- Kidney disease or
- Obesity, or history of—Use with caution. These conditions may increase risk for more serious side effects.
Uses of MonoNessa
- It is used to prevent pregnancy.
- It is used to treat pimples (acne).
- It may be given to you for other reasons. Talk with the doctor.
What are some other side effects of MonoNessa?
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
- Weight gain.
- Headache.
- Upset stomach or throwing up.
- Gas.
- Feeling nervous and excitable.
- Belly pain.
- Enlarged breasts.
- Tender breasts.
- Period (menstrual) changes. These include spotting or bleeding between cycles.
- This medicine may cause dark patches of skin on your face. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.
These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.
If OVERDOSE is suspected
If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.
How do I store and/or throw out MonoNessa?
- Store at room temperature.
- Protect from light.
- Store in a dry place. Do not store in a bathroom.
- Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
- Check with your pharmacist about how to throw out unused drugs.
Adverse Reactions
The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:
- Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions (5.1)]
- Vascular events [see Warnings and Precautions (5.1)]
- Liver disease [see Warnings and Precautions (5.2)]
Adverse reactions commonly reported by COC users are:
- Irregular uterine bleeding
- Nausea
- Breast tenderness
- Headache
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
MonoNessa
The safety of MonoNessa was evaluated in 1,647 healthy women of child-bearing potential who participated in 3 clinical trials and received at least 1 dose of MonoNessa for contraception. Two trials were randomized active-controlled trials and 1 was an uncontrolled open-label trial. In all 3 trials, subjects were followed for up to 24 cycles.
Common Adverse Reactions (≥ 2% of subjects): The most common adverse reactions reported by at least 2% of the 1,647 women were the following in order of decreasing incidence: headache/migraine (32.9%), abdominal/gastrointestinal pain (7.8%), vaginal infection (8.4%), genital discharge (6.8%), breast issues (including breast pain, discharge, and enlargement) (6.3%), mood disorders (including depression and mood altered) (5.0%), flatulence (3.2%), nervousness (2.9%), and rash (2.6%).
Adverse Reactions Leading to Study Discontinuation: Over the three trials, between 11 to 21% of subjects discontinued the trial due to an adverse reaction. The most common adverse reactions (≥1%) leading to discontinuation were: metrorrhagia (6.9%), nausea/vomiting (5.0%), headache (4.1%), mood disorders (including depression and mood altered) (2.4%), premenstrual syndrome (1.7%), hypertension (1.4%), breast pain (1.4%), nervousness (1.3%), amenorrhea (1.1%), dysmenorrhea (1.1%), weight increased (1.1%), and flatulence (1.1%).
Serious Adverse Reactions: breast cancer (1 subject), mood disorders including depression, irritability, and mood swings (1 subject), myocardial infarction (1 subject), and venous thromboembolic events including pulmonary embolism (1 subject) and deep vein thrombosis (DVT) (1 subject).
TriNessa
The safety of TriNessa was evaluated in 4,826 healthy women of child-bearing potential who participated in 6 clinical trials and received at least 1 dose of TriNessa for contraception. Two trials were randomized active-controlled trials and 4 were uncontrolled open-label trials. In 3 trials, subjects were followed for up to 24 cycles; in 2 trials, subjects were followed for up to 12 cycles; and in 1 trial, subjects were followed for up to 6 cycles.
Common Adverse Reactions (≥ 2% of subjects): The most common adverse reactions reported by at least 2% of the 4,826 women were the following in order of decreasing incidence: headache/migraine (33.6%), breast issues (including breast pain, enlargement, and discharge) (8.0%), vaginal infection (7.1%), abdominal/gastrointestinal pain (5.6%), mood disorders (including mood alteration and depression) (3.8%), genital discharge (3.2%), and changes in weight (including weight fluctuation, increased or decreased) (2.5%).
Adverse Reactions Leading to Study Discontinuation: Over the trials, between 9 to 27% of subjects discontinued the trial due to an adverse reaction. The most common adverse reactions (≥1%) leading to discontinuation were: metrorrhagia (4.3%), nausea/vomiting (2.8%), headache/migraine (2.4%), mood disorders (including depression and mood altered) (1.1%), and weight increased (1.1%).
Serious Adverse Reactions: breast cancer (1 subject), carcinoma of the cervix in situ (1 subject), hypertension (1 subject), and migraine (2 subjects).
Postmarketing Experience
The following additional adverse drug reactions have been reported from worldwide postmarketing experience with norgestimate/ethinyl estradiol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Infections and Infestations: Urinary tract infection;
Neoplasms Benign, Malignant and Unspecified (Incl. Cysts and Polyps): Breast cancer, benign breast neoplasm, hepatic adenoma, focal nodular hyperplasia, breast cyst;
Immune System Disorders: Hypersensitivity;
Metabolism and Nutrition Disorders: Dyslipidemia;
Psychiatric Disorders: Anxiety, insomnia;
Nervous System Disorders: Syncope, convulsion, paresthesia, dizziness;
Eye Disorders: Visual impairment, dry eye, contact lens intolerance;
Ear and Labyrinth Disorders: Vertigo;
Cardiac Disorders: Tachycardia, palpitations;
Vascular Events: Deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, hot flush, venous thrombosis (including Budd Chiari Syndrome and hepatic vein thrombosis);
Arterial Events: Arterial thromboembolism, myocardial infarction, cerebrovascular accident;
Respiratory, Thoracic and Mediastinal Disorders: Dyspnea;
Gastrointestinal Disorders: Pancreatitis, abdominal distension, diarrhea, constipation;
Hepatobiliary Disorders: Hepatitis;
Skin and Subcutaneous Tissue Disorders: Angioedema, erythema nodosum, hirsutism, night sweats, hyperhidrosis, photosensitivity reaction, urticaria, pruritus, acne;
Musculoskeletal, Connective Tissue, and Bone Disorders: Muscle spasms, pain in extremity, myalgia, back pain;
Reproductive System and Breast Disorders: Ovarian cyst, suppressed lactation, vulvovaginal dryness;
General Disorders and Administration Site Conditions: Chest pain, asthenic conditions.
How Supplied/Storage and Handling
How Supplied
MonoNessa
MonoNessa Tablets are available in a blister card with a VERIDATE Tablet Dispenser (unfilled) and VERIDATE refills: (NDC 52544-247-28)
Each blister card (28 tablets) contains in the following order:
- 21 blue, round, biconvex, coated tablet imprinted "WPI" on one side and "526" on the other side of the tablet contains 0.250 mg norgestimate and 0.035 mg ethinyl estradiol
- 7 dark green round, biconvex, coated tablet (non-hormonal placebo) imprinted "WPI" on one side and "P" on the other side contains inert ingredients
TriNessa
TriNessa Tablets are available in a blister card with a VERIDATE Tablet Dispenser (unfilled) and VERIDATE refills: (NDC 52544-248-28)
Each blister card (28 tablets) contains in the following order:
- 7 white, round, biconvex, coated tablet imprinted "WPI" on one side and "524" on the other side of the tablet contains 0.180 mg norgestimate and 0.035 mg ethinyl estradiol
- 7 light blue, round, biconvex, coated tablet imprinted "WPI" on one side and "525" on the other side of the tablet contains 0.215 mg norgestimate and 0.035 mg ethinyl estradiol
- 7 blue, round, biconvex, coated tablet imprinted "WPI" on one side and "526" on the other side of the tablet contains 0.250 mg norgestimate and 0.035 mg ethinyl estradiol
- 7 dark green round, biconvex, coated tablet (non-hormonal placebo) imprinted "WPI" on one side and "P" on the other side contains inert ingredients
Storage Conditions
- Store at 20–25°C (68–77°F); excursions permitted to 15° to 30°C (59° to 86°F).
- Protect from light.
- Keep out of the reach of children.